Original Article

WBC Count and WBC to Hb Ratio Could Predict Short-Term Recurrence Rate in Multiple Myeloma Patients Underwent Autologous Stem Cell Transplantation

Abstract

Multiple myeloma (MM) is a hematologic malignancy with a variable clinical course. We investigated the prognostic role of routine laboratory factors including CBC indices and serum vitamin D levels to predict MM recurrence after receiving an autologous stem cell transplant (ASCT). 29 patients were enrolled. Before ASCT, demographic data and CBC, serum Cr, and Vit D levels were obtained. Patients underwent bone marrow aspiration (BMA) and biopsy (BMB) before ASCT and pretransplant plasma cell counts were also evaluated. Patients were followed for 6 months and BMA and biopsy were done in the 3rd and 6th month of the follow-up to detect recurrence. Overall, 9 patients were reported to have recurrence. The patient's WBC count mean was 13.3±11.6. WBC count was lower in patients with overall recurrence (P=0.005). Patients were divided into 2 groups according to WBC count (<5.5 109/L and ≥5.5 109/L) and we found that WBC count <5.5 109/L was associated with increased risk of recurrence by 15.2 times (Odds ratio: 15.2, 95%CI: 1.4-168, P=0.005). We also evaluated Wbc to Hb ratio (Wbc/Hb) and found that Wbc/Hb <1 had a significant statistical relationship with overall recurrence (P=0.026) as patients with WBC/Hb <1 were in 9.8 times increased risk of recurrence (Odds ratio:9.8, 95% CI: 2-93.5, P=0.026). pretransplant WBC <5.5 109/L and WBC/Hb <1 were associated with 9.8 and 15.2 times increased risk of myeloma recurrence and could be useful predictive factors for a patient's short-term recurrence.

1. Kyle RA, Gertz MA, Witzig TE, Lust JA, Lacy MQ, Dispenzieri A, et al. Review of 1027 patients with newly diagnosed multiple myeloma. Mayo Clin Proc 2003;78:21-33.
2. Mateos MV, San Miguel JF. Management of multiple myeloma in the newly diagnosed patient. Hematology Am Soc Hematol Educ Program 2017;2017:498-507.
3. Joseph NS, Gentili S, Kaufman JL, Lonial S, Nooka AK. High-risk Multiple Myeloma: Definition and Management. Clin Lymphoma Myeloma Leuk 2017;17S:S80-7.
4. Kumar L, Ramavath D, Kataria B, Tiwari A, Raj A, Chellapuram SK, et al. High-dose chemotherapy followed by autologous stem cell transplant for multiple myeloma: Predictors of long-term outcome. Indian J Med Res 2019;149:730-9.
5. Szudy-Szczyrek A, Szczyrek M, Soroka-Wojtaszko M, Hus M. New prognostic biomarkers in multiple myeloma. Postepy Hig Med Dosw (Online) 2016;70:811-9.
6. Greipp PR, San Miguel J, Durie BG, Crowley JJ, Barlogie B, Bladé J, et al. International staging system for multiple myeloma. J Clin Oncol 2005;23:3412-20.
7. Dawson AA, Ogston D. Factors influencing the prognosis in myelomatosis. Postgrad Med J 1971;47:635-8.
8. Bataille R, Durie BG, Grenier J, Sany J. Prognostic factors and staging in multiple myeloma: a reappraisal. J Clin Oncol 1986;4:80-7.
9. Patriarca F. Frontline therapy in multiple myeloma: fast start for a long game. Lancet Haematol 2019;6:e600-1.
10. Tangen JM, Tjønnfjord GE, Gulbrandsen N, Gedde-Dahl T, Stormorken E, Anderson K, et al. Improved outcome in patients following autologous stem cell transplantation for multiple myeloma in south eastern Norway 2001-2010: a retrospective, population based analysis. BMC Cancer 2018;18:801.
11. Munker R, Monohan G. Progress in multiple myeloma. Indian J Med Res 2019;149:693-4.
12. Aggarwal M, Agrawal N, Yadav N, Verma P, Ahmed R, Mehta P, et al. Autologous stem cell transplantation in first remission is associated with better progression-free survival in multiple myeloma. Ann Hematol 2018;97:1869-77.
13. Hari P. Recent advances in understanding multiple myeloma. Hematol Oncol Stem Cell Ther 2017;10:267-71.
14. Dhakal B, Szabo A, Chhabra S, Hamadani M, D'Souza A, Usmani SZ, et al. Autologous Transplantation for Newly Diagnosed Multiple Myeloma in the Era of Novel Agent Induction: A Systematic Review and Meta-analysis. JAMA Oncol 2018;4:343-50.
15. Liu S, Shi J, Guo H, Xu F, Wei M, Sun K, et al. Prognostic Significance Of The Inflammatory Index-Based Scoring System In Patients Preliminarily Diagnosed With Multiple Myeloma In The Bortezomib-Based Chemotherapy Era. Cancer Manag Res 2019;11:9409-20.
16. Al Saleh AS, Sidiqi MH, Dispenzieri A, Kapoor P, Muchtar E, Buadi FK, et al. Hematopoietic score predicts outcomes in newly diagnosed multiple myeloma patients. Am J Hematol 2020;95:4-9.
17. Ng AC, Kumar SK, Rajkumar SV, Drake MT. Impact of vitamin D deficiency on the clinical presentation and prognosis of patients with newly diagnosed multiple myeloma. Am J Hematol 2009 ;84:397-400.
18. Yang Y, Liu Z, Wang H. Peripheral Absolute Lymphocyte Count: An Economical and Clinical Available Immune-Related Prognostic Marker for Newly Diagnosed Multiple Myeloma. Med Sci Monit 2020;26:e923716-1-8.
19. Bashir Q, Khan H, Orlowski RZ, Amjad AI, Shah N, Parmar S, et al. Predictors of prolonged survival after allogeneic hematopoietic stem cell transplantation for multiple myeloma. Am J Hematol 2012;87:272-6.
20. Pawlyn C, Davies FE. Toward personalized treatment in multiple myeloma based on molecular characteristics. Blood 2019;133:660-75.
Files
IssueVol 61 No 4 (2023) QRcode
SectionOriginal Article(s)
DOI https://doi.org/10.18502/acta.v61i4.13171
Keywords
Multiple myeloma Complete blood count Recurrence Prognosis
Rights and permissions
Creative Commons License This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
How to Cite
1.
Mojdeganlou H, Abbasi A, Asghari R. WBC Count and WBC to Hb Ratio Could Predict Short-Term Recurrence Rate in Multiple Myeloma Patients Underwent Autologous Stem Cell Transplantation. Acta Med Iran. 2023;61(4):211-215.